A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/497 (2006.01) A61K 31/337 (2006.01) A61K 31/4164 (2006.01) A61K 31/4745 (2006.01) A61K 31/475 (2006.01) A61K 31/675 (2006.01) A61K 31/704 (2006.01) A61K 31/7048 (2006.01) A61K 31/7068 (2006.01) A61K 33/24 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) C07D 403/06 (2006.01)
Patent
CA 2672933
The invention relates to a therapeutic composition which contains as an active ingredient, a pharmaceutical, particularly 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide and is applied in combination with one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or R-ICE and R-DHAP, which is a rituximab-containing combination regimen. The composition of the invention is useful for treatment of all solid cancers and lymphomas, preferably skin cancer, bladder cancer, breast cancer, uterine cancer, ovarian cancer, prostate cancer, lung cancer, colon cancer, pancreatic cancer, renal cancer, stomach cancer and the like. In particular, it is expected as a therapeutic agent for cancer resistant to other anticancer agents.
L'invention porte sur une composition thérapeutique qui contient, comme ingrédient actif, un produit pharmaceutique, en particulier le bromure de 1-(2-méthoxyéthyl)-2-méthyl-4,9-dioxo-3-(pyrazin-2-ylméthyl)-4,9-dihydro-1H-naphto[2,3-d]imidazol-3-ium, et est appliquée en combinaison avec un ou plusieurs agents anti-cancer choisis dans le groupe constitué par la carboplatine, la cisplatine, le paclitaxel, la vinorelbine, la gemcitabine, l'irinotécan, le docétaxel, la doxorubicine, la dacarbazine et le rituximab, ou R-ICE et R-DHAP, qui est un régime de combinaison contenant du rituximab. La composition de l'invention est utile pour le traitement de tous les cancers solides et des lymphomes, de préférence, le cancer de la peau, le cancer de la vessie, le cancer du sein, le cancer utérin, le cancer des ovaires, le cancer de la prostate, le cancer des poumons, le cancer du côlon, le cancer du pancréas, le cancer du rein, le cancer de l'estomac et similaires. En particulier, la composition est attendue en tant qu'agent thérapeutique pour lutter contre un cancer résistant aux autres agents anti-cancer.
Kita Aya
Koutoku Hiroshi
Nakahara Takahito
Yamanaka Kentaro
Astellas Pharma Inc.
Dennison Associates
LandOfFree
Method of treating cancer by a combined therapy of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating cancer by a combined therapy of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating cancer by a combined therapy of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1968679